Suggested remit - To appraise the clinical and cost effectiveness of treosulfan with fludarabine within its marketing authorisation as a conditioning treatment for non-malignant diseases prior to allogeneic haematopoietic stem cell transplantation.
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
- ID number:
- 1540
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 December 2019 | Following the scoping exercise this topic was not referred to NICE for a Technology Appraisal. The block scoping report containing this topic is published here; https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/block-scoping-reports (Batch 65) |
| 24 January 2019 - 21 February 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual